261 related articles for article (PubMed ID: 26813593)
1. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
3. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
4. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.
Zhou CJ; Zhang QH; Zhang TG; Sun SZ; Li H; Wang Y; Liu ZY
Pathol Oncol Res; 2009 Jun; 15(2):153-8. PubMed ID: 18941930
[TBL] [Abstract][Full Text] [Related]
5. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic features of cystic hypersecretory lesion of the breast].
Bi R; Cheng Y; Yu B; Shui R; Yang W; Xu X
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):25-9. PubMed ID: 24713245
[TBL] [Abstract][Full Text] [Related]
7. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.
Mao X; Qiao Z; Fan C; Guo A; Yu X; Jin F
Oncol Rep; 2016 Oct; 36(4):1868-74. PubMed ID: 27498697
[TBL] [Abstract][Full Text] [Related]
9. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
10. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
11. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
[TBL] [Abstract][Full Text] [Related]
12. [Papillary lesions of the breast].
Ni YB; Tse GM
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546
[No Abstract] [Full Text] [Related]
13. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
14. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
15. Utility of cytokeratin 5/6 and high-molecular-weight keratin in evaluation of cauterized surgical margins in excised specimens of breast ductal carcinoma in situ.
Nayak A; Bhuiya TA
Ann Diagn Pathol; 2011 Aug; 15(4):243-9. PubMed ID: 21420886
[TBL] [Abstract][Full Text] [Related]
16. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
Ding Y; Ruan Q
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):405-7. PubMed ID: 17120733
[TBL] [Abstract][Full Text] [Related]
17. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
18. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
19. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
